Savara Pharmaceuticals Культура компании

Mr. Robert Neville, also known as Rob, Co-founded Savara Inc. in June 2008 and has been its Chief Executive Officer since June 2008. Mr. Neville has been the Executive Chairman of Savara, Inc. since June 2008 Mr. Neville Co-founded Evity, Inc. in 1999 and served as its Chief Executive Officer from June 1998 to May 2000. Mr. Neville founded the management consulting company Clockwise Consulting. From January 2003 to December 2004, he served as Managing Director of Clockwise Consulting, where he worked with the Texas Children's Hospital and the Baylor College of Medicine to develop an ICU-based monitoring and diagnostic device. From June 2000 to December 2002, he served as Vice President of Engineering at BMC Software, a software company providing information technology management solutions, where he oversaw the integration and expansion of the product line based on the acquisition of his previous company, Evity, Inc. Mr. Neville partnered with local biotech companies, the Texas Children's Hospital and the Baylor College of Medicine in Houston to develop an ICU-based monitoring and diagnostic device. He was honored as a finalist for the Ernst & Young Entrepreneur of the Year award. He holds a post-graduate Engineering degree from the University of Natal South Africa.

Dr. John Lord, PhD serves as the Head of Pharmaceutical Development at Savara, Inc. Dr. Lord is responsible for all CMC activities. He has over seventeen years of inhalation product development experience working on products ranging from early formulation to commercial. His experience includes leadership roles at numerous pharmaceutical companies including Rh???ne-Poulenc Rorer and Nektar Therapeutics, with a focus on pharmaceutical development of inhalation products. He has experience across multiple inhalation formulation and device technologies including dry powder inhalers, pressurized metered dose inhalers and nebulizers. Dr. Lord holds a Ph.D. in Pharmaceutics from the University of Bath where he studied particle interactions in dry powder inhalations.

Dr. Jaakko Taneli Jouhikainen, MD, Ph.D., M.B.A., has been the President and Chief Operating Officer at Savara Inc. since April 2017 and October 2009 respectively. Dr. Jouhikainen served as Head of Product Development of Savara, Inc and responsible for product and platform development. Dr. Jouhikainen is a veteran executive in the medical and pharmaceutical industries. Dr. Jouhikainen serves as Vice President Business Development and Strategy of LAB Pharma Ltd. Dr. Jouhikainen served as Acting Chief Executive Officer of Akela Pharma Inc. (formerly Lab International Inc.) until September 2009. He served as President, Chief Executive Officer and Vice-President, Business Development & Strategy of Focus Inhalation Oy (Focus). He served as President of LAB Pharma OY, a division of Lab International Inc. since March 25, 2004. He served as Senior Vice President of Product Development and Corporate Development and a Vice President of Corporate Development of Akela Pharma Inc. He served as Director, Clinical Research of Leiras Oy, Research & Development/ Schering AG. He served as a Member of Clinical Advisory Board at Savara Inc. He has solid experience in pharmaceutical product development and also has a combination of big pharma R&D experience, as well as an in-depth knowledge of the pulmonary drug delivery industry and inhalation product development. Prior to this, he has held various managerial positions at Leiras and Schering and was a Member of the initial management team of Focus when Lab International Inc. was spun off from Schering in 2000. He served as Chairman of the Board for Spectrum Medical Sciences. He is also a published author in scientific publications in peer- reviewed scientific journals. Dr. Jouhikainen is a licentiate of Medicine, Doctor of Medical Sciences and MBA.

Mr. Kenny Frazier serves as Head of Clinical Development at Savara Inc. Mr. Frazier served as Vice President of Clinical Development & Regulatory Affairs at Opexa Therapeutics, Inc. He served as the head of clinical development and regulatory affairs for Opexa Therapeutics. Mr. Frazier has more than 25 years of experience in clinical development including six years in contract research organizations and eighteen years in biotech and large pharma. Prior to joining Opexa, Mr. Frazier served as the Head of Clinical Operations for Lexicon Pharmaceuticals, a mid-sized biopharmaceutical company focused on the development of novel compounds in large and orphan indications. Mr. Frazier managed operational activities of early (FIH) development through late stage phase 3 clinical trials across a number of therapeutic areas including diabetes, oncology, rheumatoid arthritis, and irritable bowel syndrome. Prior to Lexicon, Mr. Frazier led clinical operations for Tanox, Inc., a small biotechnology company focused on the development of monoclonal antibodies for the treatment of peanut allergies and HIV. Prior to Tanox, Inc., Mr. Frazier spent six years as Director of Clinical Operations with DuPont Pharmaceuticals where he led the development of field operations, drug safety and project management to support clinical trials in cardiovascular, rheumatoid arthritis, HIV, CNS and oncology. Mr. Frazier holds a Bachelor of Science degree in Biology from Texas Tech University.

Michael Ciesla serves as the VP Finance / Consulting CFO / Director SEC Reporting for Savara Inc.. Michael started at Savara Inc. in March of 2011. Michael is based in the Austin, Texas Area.

Dave Lowrance serves as the CFO for Savara Pharmaceuticals. Dave started at Savara Pharmaceuticals in November of 2016. Dave is based in the Austin, Texas Area.

Kate McCabe serves as the VP, Legal Affairs for Savara Inc.. Kate started at Savara Inc. in March of 2018. Kate is based in the Austin, Texas Area.

John Lord serves as the Vice President, Pharmaceutical Development of Savara Inc.. John currently resides in the Austin, Texas Area.